Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEDI 0618

Next Previous
X
Search
Drug Profile

MEDI 0618

Alternative Names: MEDI-0618

Latest Information Update: 25 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Analgesics; Monoclonal antibodies
  • Mechanism of Action PAR 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Migraine
  • Phase I Pain

Most Recent Events

  • 07 Oct 2024 Phase-II clinical trials in Migraine (Treatment-experienced) in USA, Czech Republic, Denmark, Germany, Hungary, Netherlands, Italy, Poland, Spain (Parenteral) (NCT06602479)
  • 19 Sep 2024 AstraZeneca plans a phase II trial for Migraine (Treatment experienced) in USA, Czech Republic, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Spain (SC) (NCT06602479)
  • 12 Dec 2023 AstraZeneca completes a Phase I development in Pain (In volunteers) is ongoing in Germany (SC) (IV) (NCT05714254)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top